Patients and tumor characteristics
NSCLC, Renal carcinoma cancer, tumor, HCC, Hepatocellular carcinoma, RCC, SRS
TUMOR, BRAIN METASTASES, NON SMALL CELL LUNG CANCER, NSCLC, METASTASES, RCC
Between October 2014 and June 2020, 251 patients for 449 treated BMs were enrolled and randomly assigned to Arm-A (121) or Arm-B (130), as shown in Fig. CONSORT flow diagram of patients enrolled in the randomized trial comparing Arm-A and Arm-BThe total number of eligible patients was 312, and 19.5% were excluded for the reasons outlined in Fig. Baseline patient, and tumor characteristics stratified for radiosurgery (SRS) modalityNo., Number; pts, Patients; SRS, Radiosurgery; KPS, Karnofsky performance scale; NSCLC, Non small cell lung cancer; RCC, Renal carcinoma cancer; GI, Gastrointestinal; HN, Head and neck; HCC, Hepatocellular carcinoma; GU, Genitourinary; EC met, Extracranial metastases; RPA, Recursive partial analysisThe number of BMs treated was 236 (53.6%) in Arm-A and 213 (47.4%) in Arm-B. Baseline BMs characteristics stratified for SRS modality are shown in Table Brain metastases (BMs) characteristics stratified for radiosurgery treatment armBMs, Brain metastases; No., Number; SRS, RadiosurgeryThe median GTV was 0.38 cmThe dose prescription was 20 Gy in 51 (21.6%) and 24 Gy in 185 (78.4%) lesions in Arm-A, while it was 24 Gy for all 213 treated lesions in Arm-B. The summary of the dosimetric parameters is given in Additional file 